LXEO
Lexeo Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +3 | 35.14M | $163.68M | +8 | −5 |
| Q1 2026 | 64 | -1 | 34.99M | $201.02M | +4 | −5 |
| Q4 2025 | 65 | +1 | 34.14M | $338.98M | +1 | — |
| Q3 2025 | 16 | +1 | 14.53M | $96.47M | +1 | — |
| Q2 2025 | 12 | -2 | 12.40M | $49.85M | — | −2 |
| Q1 2025 | 11 | +1 | 6.39M | $22.16M | +2 | −1 |
| Q4 2024 | 10 | +3 | 6.97M | $45.84M | +3 | — |
| Q3 2024 | 6 | +1 | 6.33M | $57.26M | +1 | — |
| Q2 2024 | 5 | — | 5.51M | $88.42M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 2.60M | — | $41.67M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 2.56M | — | $41.04M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 296.61K | — | $4.76M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 296.61K | — | $4.76M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 37.47K | — | $600,955 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 22.10K | — | $354,500 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 22.10K | — | $354,500 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 137 holders, 79.80M shares, $457.81M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.35K sh · $16,562
Officer · 1.30K sh · $6,464
Officer · 4.12K sh · $20,203
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology